Hemostatic sponge

Patent metadata

Field	Value
Publication number	US-12576181-B2
Application number	US-201916548402-A
Country	US
Kind code	B2
Filing date	Aug 22, 2019
Priority date	Jun 16, 2009
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

First claim

The invention claimed is:

1 . A hemostatic porous sponge having a first, injury-facing side, and an oppositely disposed second side, the hemostatic porous sponge comprising:
a fibrous biomaterial matrix formed of a fibrous biomaterial comprising gelatin or collagen, the fibrous biomaterial matrix being present in an amount of 1% to 50% of the porous sponge in a dried state (w/w %); an adhesive layer continuously coated on the first, injury-facing side of the sponge, the adhesive layer comprising a cross-linkable synthetic polymer comprising succinimidyl groups; and a supporting layer provided on the second side of the sponge, the supporting layer being an active hemostatic layer having a greater tensile strength than the fibrous biomaterial matrix, wherein the sponge is configured to absorb fluid from a site of injury.

2 . The sponge according to claim 1 , wherein said adhesive layer comprises a bioresorbable polymer.

3 . The sponge according to claim 1 , wherein the adhesive layer further comprises a cross-linkable component that cross-links with the synthetic polymer comprising succinimidyl groups under reaction enabling conditions.

4 . The sponge according to claim 1 being freeze-dried or air-dried.

5 . The sponge according to claim 1 , wherein said supporting layer comprises a bioresorbable polymer.

6 . The sponge according to claim 1 , wherein said supporting layer has a greater density than the matrix material.

7 . The sponge according to claim 1 , wherein the polymer is a hydrophilic polymer.

8 . The sponge according to claim 1 , wherein the adhesive layer comprises only one synthetic polymer.

9 . The sponge according to claim 1 , wherein the polymer comprises active side groups for cross-linking and adherence to a tissue.

10 . A method of treating an injury comprising administering a hemostatic porous sponge to a site of injury, the hemostatic porous sponge having a first, injury-facing side, and an oppositely disposed second side and comprising:
a matrix of a fibrous biomaterial comprising gelatin or collagen; an adhesive layer continuously coated on a first injury facing side of the sponge, the adhesive layer comprising a synthetic polymer comprising succinimidyl groups; and a supporting layer provided on the second side of the sponge, the supporting layer being an active hemostatic layer having a greater tensile strength than the fibrous biomaterial matrix, wherein the sponge is configured to absorb fluid from the site of injury.

11 . The method according to claim 10 , wherein said injury comprises a wound, a hemorrhage, damaged tissue and/or bleeding tissue.

12 . The method according to claim 10 , wherein the polymer is a hydrophilic polymer.

13 . The method according to claim 10 , wherein the adhesive layer comprises only one synthetic polymer.

14 . The method according to claim 10 , wherein the polymer comprises active side groups for cross-linking and adherence to a tissue.

15 . A hemostatic porous sponge having a first, injury-facing side, and an oppositely disposed second side, the hemostatic porous sponge comprising:
a fibrous biomaterial matrix formed of a fibrous biomaterial comprising gelatin or collagen, the fibrous biomaterial matrix being present in an amount of 1% to 50% of the porous sponge in a dried state (w/w %); and an adhesive layer consisting of a first cross-linkable component and a second cross-linkable component configured to cross-link with the first cross-linkable component under reaction enabling conditions.

Assignees

• Baxter Int
• Baxter Healthcare Sa

Inventors

• Hoefinghoff Joris
• Hedrich Hans Christian

Classifications

• A61L2300/418

  Agents promoting blood coagulation, blood-clotting agents, embolising agents · CPC title

• A61L15/64

  specially adapted to be resorbable inside the body · CPC title

• A61L15/44

  Medicaments · CPC title

• A61L15/26 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)} · CPC title

• A61L2400/04

  Materials for stopping bleeding · CPC title